JohnNathanAllanMD

PubMed

• 53 citations
  Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
  Anthony R. Mato, Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander
  American Journal of Hematology. 2018-11-01
• 49 citations
  Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.
  Francesca Arruga, Branimir Gizdić, Cinzia Bologna, Simona Cignetto, Roberta Buonincontri
  Leukemia. 2017-09-01
• 8 citations
  Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
  Yen-Chun Liu, Elizabeth Margolskee, John N. Allan, Susan Mathew, Erica B. Bhavsar
  Modern Pathology. 2020-03-01

Journal Articles

• Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States  
  Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica

Abstracts/Posters

• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in RichterÍs Syndrome (RS)
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Dual PI3K-_/_ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models
  John N. Allan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• CD79b Expression in Richter's Transformation 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all